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Cancer incidence is one of the most fundamental param-
eters in cancer epidemiology. Incidence encompasses both 
the natural history of a malignancy and the effects of 
interventions to reduce occurrence [1]. Accurate estimates 
of cancer incidence are vital elements in ascertaining the 
etiology of cancers, planning for public health burden, 
and monitoring the effects of interventions. In resource- 
rich settings, given the better equipped medical infrastruc-
ture, virtually all instances of cancer are diagnosed and 
recorded. These diagnoses are then placed into context 
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Abstract
In resource- limited areas, such as sub- Saharan Africa, problems in accurate 
cancer case ascertainment and enumeration of the at- risk population make it 
difficult to estimate cancer incidence. We took advantage of a large well- 
enumerated healthcare system to estimate the incidence of Kaposi sarcoma (KS), 
a cancer which has become prominent in the HIV era and whose incidence 
may be changing with the rollout of antiretroviral therapy (ART). To achieve 
this, we evaluated HIV- infected adults receiving care between 2007 and 2012 
at any of three medical centers in Kenya and Uganda that participate in the 
East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) 
Consortium. Through IeDEA, clinicians received training in KS recognition and 
biopsy equipment. We found that the overall prevalence of KS among 102,945 
HIV- infected adults upon clinic enrollment was 1.4%; it declined over time at 
the largest site. Among 140,552 patients followed for 319,632 person- years, the 
age- standardized incidence rate was 334/100,000 person- years (95% CI: 314–
354/100,000 person- years). Incidence decreased over time and was lower in 
women, persons on ART, and those with higher CD4 counts. The incidence 
rate among patients on ART with a CD4 count >350 cells/mm3 was 32/100,000 
person- years (95% CI: 14–70/100,000 person- years). Despite reductions over 
time coincident with the expansion of ART, KS incidence among HIV- infected 
adults in East Africa equals or exceeds the most common cancers in resource- 
replete settings. In resource- limited settings, strategic efforts to improve cancer 
diagnosis in combination with already well- enumerated at- risk denominators 
can make healthcare systems attractive platforms for estimating cancer 
incidence.
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of the underlying denominator of persons at risk by the 
creation of incidence rates [2]. The denominators are 
typically derived from municipally funded complete enu-
merations (i.e., a census) of geographic populations. In 
contrast, in resource- limited settings, such as sub- Saharan 
Africa, there is limited infrastructure for cancer diagnosis, 
and even when  diagnosed, not all cancers are formally 
recorded [3]. Further, there are challenges in enumerating 
the denominator from which cancers arise. The WHO- 
sponsored Cancer Incidence in Five (“CI5”) Continents 
project deemed only 4 out of 25 registries from countries 
in sub- Saharan Africa to have sufficient quality [4, 5], 
and even within these countries, there are issues in both 
ascertainment of total cancer cases and the underlying 
denominator.
Kaposi sarcoma (KS) is an example of a malignancy 
in a resource- limited setting which would benefit from 
knowledge about incidence. From a perspective of 
 percentage of all recorded cancers, KS was among the 
most common cancers in sub- Saharan Africa even before 
the human immunodeficiency virus (HIV) epidemic [6, 
7], and it experienced explosive growth as HIV  infection 
spread [8, 9]. The clinical relevance of KS includes both 
cosmetic disfigurement and considerable morbidity and 
mortality. In persons untreated for HIV, 1- year mortality 
after KS diagnosis in sub- Saharan Africa is 60% to 70% 
[10, 11]. Even among persons treated with antiretroviral 
therapy (ART), those with KS have about a fourfold higher 
rate of death [12]. In resource- rich settings, ART has 
substantially reduced KS incidence, but because of the 
lack of robust sources of incidence data, the status in 
sub- Saharan Africa is less clear aside from an initial report 
from South Africa [13]. As is true for many cancers, 
changes in KS incidence in resource- replete settings cannot 
necessarily be  extrapolated to resource- limited ones. 
Differences between  settings regarding the strain of the 
etiologic viral agent (Kaposi sarcoma- associated herpesvi-
rus, KSHV), ambient HIV strains, human host, and poten-
tially other environmental cofactors dictate that KS 
incidence must be directly measured in Africa for it to 
be relevant.
To overcome the challenges inherent in a resource- 
limited setting, we used a newly assembled collection 
of healthcare system- derived databases, the International 
Epidemiological Databases to Evaluate AIDS (IeDEA) 
Consortium in East Africa, to derive a well- substantiated 
(in terms of numerator and denominator) estimate of 
cancer incidence in a large representative population of 
HIV- infected adults in sub- Saharan Africa. We focused 
on KS, not only because of its ease of measurement 
and clinical relevance, but also to demonstrate how add-
ing the selective measurements to an already well- 
enumerated healthcare system- based population has the 
potential to be a powerful platform for the study of 
other cancers.
Methods
Overall design
We performed a cohort analysis among HIV- infected adults 
(≥18 years old) receiving care at one of three medical 
centers in Kenya and Uganda that participate in the East 
Africa IeDEA Consortium. Established in 2005 by the U.S. 
National Institutes of Health, the IeDEA Consortium has 
as its main procedural objective the harmonizing of data 
collected by geographically disparate, but representative, 
cohorts of persons infected with HIV or at risk for HIV 
[14–16]. The scientific goal is to generate inferences about 
the natural or treated history of HIV, particularly regard-
ing uncommon exposures or outcomes for which large 
samples are needed.
Study population
We included data from HIV- infected adults who were 
receiving care at one of three medical care systems: the 
Immune Suppression Syndrome (ISS) Clinic located at 
the Mbarara Regional Referral Hospital in Mbarara, Uganda 
[17]; the Infectious Diseases Institute (IDI) at Mulago 
National Referral Hospital in Kampala, Uganda [18]; and 
the Academic Model Providing Access to Healthcare 
(AMPATH) network in western Kenya [19]. Briefly, the 
ISS Clinic, located in southwestern Uganda, has cared for 
over 20,000 HIV- infected adults since it began in 1998. 
Since 2002, the IDI has offered HIV/AIDS care to over 
30,000 patients; the patient base is mainly from the greater 
urban Kampala area with a small proportion from outside 
Kampala. Of note, during 2008 to 2011, the IDI conducted 
a treatment study of KS, in which all patients became 
part of the IDI clinic. AMPATH was established in 2001 
and has cumulatively enrolled over 160,000 HIV- infected 
patients at 60 different clinics. The average number of 
patients cared for per year during the study period was 
55,502 at AMPATH, 10,428 at IDI, and 8329 at the ISS 
Clinic. Each of these systems provides the standard- of- care 
management of HIV disease, including counseling, free 
cotrimoxazole prophylaxis, and free ART. We included any 
patient with at least one clinic visit between January 2007 
and July 2012, incorporating all patients newly enrolling 
in January 2007 or later as well as those who enrolled 
prior to 2007. Patients were followed, for the purpose of 
this analysis, until the earliest occurrence of KS, transfer 
to another healthcare facility, death, or administrative 
database closure. Approval for this research was granted 
by each site’s institutional review board.
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Measurements
KS
Prior to 2007, at all sites, the diagnosis of KS was largely 
clinical only (i.e., by visual inspection) with rare pathologic 
confirmation. In January 2007, skin punch biopsy capacity 
for histopathologic diagnosis (provided free to patients) 
was introduced at IDI, followed in October 2008 at the 
ISS Clinic and AMPATH. Through support from IeDEA, 
clinicians received training in the recognition of KS, the 
importance of early pathologic diagnosis, and how to 
perform a biopsy. Biopsy interpretations were adjudicated 
by dermatopathologists at the University of California, 
San Francisco, who had available to them, at their discre-
tion, the use of immunohistochemical staining against the 
latency- associated nuclear antigen of KSHV. For the pur-
pose of this analysis, a KS diagnosis was defined by the 
presence of a clinical- only diagnosis of KS or a clinical 
KS diagnosis accompanied by definitive or indeterminate 
pathologic confirmation. When there were both a date 
of diagnosis on clinical grounds and a date of pathologic 
confirmation, we used the earlier date as the overall date 
of diagnosis. Patients with a clinical diagnosis and a nega-
tive biopsy were not considered to have KS.
Other variables
Age, sex, weight, ART use, hemoglobin, and CD4+ T- cell 
count were obtained from the ambient electronic medical 
record databases. Because ART adherence information was 
not recorded routinely, we assumed that once started on 
ART, patients continued on ART.
Statistical analysis
In an analysis of KS prevalence, we first determined the 
frequency of KS among patients upon enrollment in their 
respective medical systems, limiting to those newly enrolled 
on or after 1 January 2007 who had also not yet started 
ART. Prevalence upon clinic enrollment in ART- unexposed 
patients serves as a rough correlate of KS incidence in the 
community and is one measure of the burden of KS facing 
HIV care clinics. Because KS might go unnoticed at an 
administratively demanding initial clinic visit, we assumed 
that any KS recorded within 30 days of enrollment was 
present at enrollment and was therefore prevalent.
For the incidence analysis, we studied all patients who 
had no diagnosis of KS, as of the time they became eligible 
for the analysis, for the subsequent occurrence of KS. 
Therefore, 1 January 1 2007 was considered time zero for 
patients enrolled prior to then, and the date of the initial 
clinic visit was time zero for those enrolled after 1 January 
2007. We calculated incidence rates, as total new cases of 
KS divided by the at- risk person- time (expressed per 100,000 
person- years), for the overall population as well as subgroups 
defined by age, sex, calendar year, medical center, ART status, 
and CD4+ T- cell count. For ART status, we classified the 
population according to person- time in which ART was not 
used (“non- ART use”) and person- time in which ART was 
used (“ART use”). Given the importance of capturing the 
early time period after ART initiation [20], we also evaluated 
person- time in which ART was used among patients who 
initiated ART under our observation (“new ART use”). As 
such, “new ART use” is a subset of the “ART use” person- 
time. Age- standardized incidence rates (ASIR) were estimated 
using both the new [21] and old [22, 23] WHO world 
standard population. Because we only had direct data on 
persons 18 years and older, we limited our primary ASIR 
estimation to adults. In an additional analysis, we estimated 
ASIR for an entire population age range by assuming zero 
incidence of KS among those <15 years. Because we recognize 
that zero incidence is unlikely, we consider this ASIR to be 
a “best case,” that is, a minimum estimate. In a sensitivity 
analysis, we assumed that any KS occurring within 30 days 
following ART initiation was present but unrecognized at 
the start of ART, and hence, we reset diagnosis date to the 
day prior to ART. Change over time in either prevalence 
or incidence was assessed with score tests for trend [24]. 
All analyses were performed with Stata (version 13.1, Stata 
Corp., College Station, TX, USA).
Results
Characteristics of the study populations
In the analysis of prevalent KS upon medical center 
enrollment, we evaluated 102,945 HIV- infected adults (See 
Figure 1), 10,519 (10%) from the ISS–Uganda, 7332 (7%) 
from the IDI–Uganda, and 85,094 (83%) from the 
AMPATH–Kenya. Their median age was 34 years, women 
comprised 66% of the sample, and the median CD4+ 
T- cell count was 253 cells/mm3 (Table 1). In the incidence 
analysis, we followed 140,552 HIV- infected adults (See 
Figure 1), 15,437 (11%) from the ISS–Uganda, 16,493 (12%) 
from the IDI–Uganda, and 108,622 (77%) from the 
AMPATH–Kenya (Table 2). At time zero, their median age 
was 35 years, women comprised 67% of the sample, 16% 
were on ART, and the median CD4+ T- cell count was 
270 cells/mm3. Of the 117,764 patients not on ART at time 
zero, 75,122 subsequently started ART during follow- up with 
9874 of these initiating ART at the enrollment visit.
Prevalence of KS at clinic enrollment
Among 102,945 patients, a total of 1409 KS diagnoses 
were made at clinic enrollment, of which 63% were 
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clinical only, 36% were biopsy confirmed, and 0.9% were 
clinical with an indeterminate biopsy. Over time, the fre-
quency of diagnoses accompanied by biopsy increased (to 
about 50%) and then plateaued (Fig. 2; Panel A). Overall, 
the prevalence of KS at clinic enrollment was 1.4% (95% 
confidence interval (CI): 1.3–1.4); it was 1.3% at the 
ISS–Uganda, 2.8% at the IDI–Uganda, and 1.3% at the 
AMPATH–Kenya (Fig. 3). At the IDI–Uganda, the spike 
in prevalence between 2008 and 2010 likely reflects the 
enrichment of patients with KS from the aforementioned 
treatment trial. Thus, KS prevalences at the AMPATH–
Kenya, and at the ISS–Uganda, are better representatives 
of disease burden in their underlying communities. At 
both of these sites, prevalence was slightly above 1% at 
the beginning of 2007. Prevalence fell at the AMPATH–
Kenya, over time (P for trend <0.001), but, at the ISS–
Uganda, there was no evidence for systematic change in 
prevalence (P for trend = 0.52).
Incidence of KS
Among the 140,552 patients who began observation without 
KS, we subsequently followed them for incident KS over 
319,605 person- years (median 1.8 years; interquartile range 
(IQR) 0.4–4.2 years). Among non- ART users, the total 
person- time was 88,566 person- years (median 1.9 years; 
IQR 0.4–4.2 years), while among ART users, it was 231,038 
person- years (median 1.8 years; IQR 0.5–3.5 years) (135,523 
person- years among new ART users; median 1.3 years; 
IQR 0.4–2.9 years). Observation ended with the develop-
ment of KS in 1025 patients, death in 8609, transfer to 
another medical facility in 6214, administrative closure 
in 76,775, and loss to follow- up in 47,929.
Of the 1025 incident KS diagnoses (76% at the AMPATH–
Kenya and 12% at both the ISS–Uganda, and IDI–Uganda), 
63% were clinical only, 36% were biopsy confirmed, and 
1.1% were biopsy indeterminate. Over time, the frequency 
Table 1. Characteristics of antiretroviral therapy- naive HIV- infected adults upon enrollment in one of three healthcare systems in East Africa (Prevalent 
KS study population).
Characteristic ISS  
n = 10,519
IDI  
n = 7,332
AMPATH  
n = 85,094
Overall  
n = 102,945
Age, years1 31 (26–38)2 33 (27–40) 35 (28–43) 34 (28–42)
Age category, years
18–19 2.9% 2.5% 1.5% 1.7%
20–24 16% 13% 10% 11%
25–29 23% 18% 17% 18%
30–34 21% 20% 20% 20%
35–39 16% 19% 18% 17%
40–44 10% 13% 13% 13%
45–49 5.8% 7.5% 9.3% 8.8%
50–54 3.0% 3.4% 5.7% 5.3%
55–59 1.3% 1.8% 3.2% 2.9%
60–64 0.8% 0.9% 1.6% 1.5%
65–69 0.5% 0.5% 0.6% 0.6%
70–74 0.2% 0.3% 0.3% 0.3%
75–79 0.1% 0.05% 0.1% 0.1%
≥ 80 0.02% 0.01% 0.04% 0.04%
Male sex 37% 35% 33% 34%
Weight, Kg3 54 (48–61)2 55 (49–62) 55 (49–62) 55 (49–62)
CD4+ T- cells, cells/mm3, 4 296 (136–493)2 270 (105–484) 247 (102–439) 253 (105–447)
CD4+ T- cells category, cells/mm3
0–50 12% 15% 14% 14%
51–100 8.1% 9.0% 10% 10%
101–200 16% 15% 18% 18%
201–350 23% 22% 22% 22%
351–500 18% 15% 16% 16%
≥ 500 24% 24% 19% 20%
Hemoglobin, mg/dl5 13 (11–14)2 12 (11–14) 12 (10–13) 12 (10–14)
ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; IDI denotes Infectious Diseases Institute in Kampala, Uganda; AMPATH 
 denotes Academic Model for Providing Access to Healthcare in western Kenya.
10.2% missing age.
2Median (interquartile range) unless otherwise noted.
32.1% missing weight.
416% missing CD4 count.
520% missing hemoglobin.
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of diagnoses accompanied by biopsy steadily increased 
(Fig. 2; Panel B). The overall KS incidence rate was 
321/100,000 person- years (95% CI: 302–341/100,000 
person- years), which did not substantively differ across 
sites: 321/100,000 person- years at the AMPATH–Kenya, 
337/100,000 person- years at the ISS–Uganda, and 
301/100,000 person- years at the IDI—Uganda (Table 3). 
When limiting inference to our observed population of 
adults age ≥18 years, the ASIR was 334/100,000 person- 
years (95% CI: 314–354/100,000 person- years) using the 
new WHO standard population and was 340/100,000 (95% 
CI: 319–361/100,000 person- years) using the older WHO 
standard population. Extending inference to the entire 
population age range (including children), the ASIR was 
247/100,000 person- years in the best- case scenario, assum-
ing zero incidence among children. Over time, overall 
incidence decreased, from a peak in 2007 of 509/100,000 
person- years to 222/100,000 person- years in 2012 (P for 
trend <0.001; Fig. 4). The incidence of KS generally reduced 
over calendar time similarly across sites.
When evaluating KS incidence among subgroups, there 
was no clear pattern associated with age, but incidence 
was higher among men at 526/100,000 person- years (95% 
CI: 483–574/100,000 person- years) compared to women 
(229/100,000 person- years; 95% CI: 210–250/100,000 person- 
years), and higher with decreasing CD4 count (Table 3). 
Among non- ART users, incidence was 411/100,000 person- 
years (95% CI: 371–455/100,000 person- years), compared 
to 286/100,000 person- years (95% CI: 265–309/100,000 
person- years) among all ART users and 394/100,000 person- 
years (95% CI: 362–429/100,000 person- years) when limited 
to the new ART users. The differences between ART users 
and non- ART users became more apparent when stratified 
by CD4+ T- cell count. For example, for patients with CD4+ 
Table 2. Characteristics at the beginning of their respective period of observation among all HIV- infected adults who were followed for the develop-
ment of incident Kaposi sarcoma at one of three healthcare systems in East Africa (Incident KS study population).
Characteristic ISS  
n = 15,437
IDI  
n = 16,493
AMPATH  
n = 108,622
Overall  
n = 140,552
Age, years1 33 (27–40)2 35 (29–41) 35 (29–43) 35 (29–43)
Age category, years
18–19 2.1% 1.2% 1.2% 1.3%
20–24 13% 9.2% 9.8% 10%
25–29 20% 16% 16% 17%
30–34 19% 20% 19% 19%
35–39 18% 21% 18% 19%
40–44 13% 17% 14% 14%
45–49 7.0% 8.0% 9.5% 9.0%
50–54 3.4% 3.7% 5.5% 5.1%
55–59 1.9% 2.1% 3.2% 2.9%
60–64 1.0% 1.1% 1.6% 1.4%
65–69 0.5% 0.5% 0.6% 0.6%
70–74 0.2% 0.2% 0.3% 0.3%
75–79 0.1% 0.07% 0.1% 0.1%
≥ 80 0.03% 0.03% 0.04% 0.04%
Male sex 37% 33% 32% 33%
Weight, Kg3 56 (49–63) 57 (51–64) 56 (50–63) 56 (50–63)
CD4+ T cells, cells/mm3, 4 316 (160–510) 292 (159–466) 262 (122–440) 270 (129–449)
CD4+ T- cells category, cells/mm3
0–50 9.3% 8.9% 12% 11%
51–100 6.9% 6.7% 9.2% 8.7%
101–200 15% 16% 18% 18%
201–350 24% 28% 25% 25%
351–500 19% 18% 17% 17%
≥ 500 26% 22% 19% 20%
Hemoglobin, mg/dl5 13 (11–14) 13 (11–14) 12 (10–14) 12 (10–14)
ART in use 20% 26% 14% 16%
ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; IDI denotes Infectious Diseases Institute in Kampala, Uganda; AMPATH 
 denotes Academic Model for Providing Access to Healthcare in western Kenya.
10.4% missing age.
2median (interquartile range) unless otherwise noted.
33.7% missing weight.
418% missing CD4 count.
528% missing hemoglobin.
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T- cell counts above 350 cell/mm3 (the commonly perceived 
immunologic safe haven), KS incidence was 146/100,000 
person- years (95% CI: 87–247/100,000 person- years) among 
non- ART users, 32/100,000 person- years (95% CI: 
14–70/100,000  person- years) among all ART users, and 
41/100,000 person- years (95% CI: 15–109/100,000 person- 
years) among new ART users.
In the sensitivity analysis, we found 94 patients diag-
nosed with KS within the first 30 days of initiating ART, 
and for these patients, we reset the date of KS diagnosis 
to the day prior to ART start. The resulting revised inci-
dence rate was 516/100,000 person- years (95% CI: 
471–565/100,000 person- years) among those not on ART, 
245/100,000 person- years (95% CI: 226–266/100,000 
person- years) among all ART users, and 325/100,000 
person- years (95% CI: 296–357/100,000 person- years) 
among only new ART users.
Discussion
When estimating cancer incidence, resource- limited set-
tings, in contrast to resource- rich ones, have difficulties 
in both the ascertainment of cancer cases (i.e., the numera-
tor in the incidence calculation) and the true at- risk 
Figure 2. Frequency of accompanying skin biopsy at the time of diagnosis of Kaposi sarcoma (KS) among HIV- infected patients over time at three 
healthcare systems in East Africa. Panel A shows instances of prevalent KS diagnosis, and panel B shows cases of incident KS. Line represents locally 
weighted scatterplot smoothing (LOWESS). Q represents quarter of the calendar year.
(A) (B)
Figure 1. Summary of the process of patient selection for the study of Kaposi sarcoma (KS) prevalence and incidence in the three healthcare systems 
in East Africa. ART denotes antiretroviral therapy.
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population (i.e., the denominator). We have demonstrated 
how a large healthcare system- based platform–East Africa 
IeDEA–can overcome many of the prior limitations of 
estimating cancer incidence in sub- Saharan Africa and 
be used to precisely estimate the incidence of KS, one 
of the most common cancers in the region. The corner-
stone of this approach is the very large population that 
is enumerated longitudinally at the individual person level 
in electronic databases with standardized coding at the 
IeDEA sites. To this large population, we enhanced KS 
diagnosis through clinician training and provision of skin 
punch biopsy equipment for histopathologic diagnosis. 
These strategic efforts increased the specificity of diagnosis 
compared to the heretofore convention of clinical- only 
diagnosis [25]; they conceivably may have also increased 
sensitivity. Accordingly, our estimate of KS incidence is 
among the first prospective estimates of cancer incidence 
at the individual level in East Africa and, we believe, 
among the least biased and most precise.
Conventionally, the gold standard approach for estimat-
ing cancer incidence in both resource- rich and resource- 
limited settings is to derive it within a defined geographic 
area. In resource- rich settings, this is accomplished by 
combining data from the population- based cancer registries 
(numerator) and a relevant geographic population census 
(denominator). The resultant incidence estimates are both 
accurate and precise because functional underlying health-
care systems diagnose and record most, if not all, cancers 
that occur, cancer registries collect these diagnoses, and 
up- to- date census data from large geographic regions 
enumerate the at- risk population. In contrast, in sub- 
Saharan Africa, the CI5 project deemed that only four 
cancer registries–each covering only a small region of a 
single country–had data of sufficient quality [4] (Table 4). 
Furthermore, even within these four registries, there are 
several challenges that threaten the veracity of the inci-
dence estimates, particularly for KS. First, cancer case 
ascertainment is largely derived from the most predictably 
Figure 3. Prevalence of Kaposi sarcoma at the time of clinic enrollment among HIV- infected patients over time at three healthcare systems in East 
Africa. Line represents locally weighted scatterplot smoothing (LOWESS). AMPATH denotes Academic Model Providing Access to Healthcare in 
western Kenya; ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; and IDI denotes Infectious Diseases Institute in Kampala, 
Uganda. Q represents quarter of the calendar year.
(A) (B)
(C) (D)
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efficient sources: pathology records, oncology clinics, and 
inpatient wards. Yet, cancer in resource- limited settings 
is frequently diagnosed on clinical grounds alone in pri-
mary care settings, may never get cared for in any higher 
facility, and hence never gets systematically recognized. 
This is especially true for KS, and it is unclear (but 
unlikely) that any of the four CI5- worthy registries scoured 
all of the outpatient records of the HIV care clinics in 
their region to detect all clinical KS diagnoses. In the 
registry believed to have the most comprehensive coverage 
of care venues (Blantyre, Malawi), only 17% of KS cases 
were pathologically confirmed [26], and this percentage 
is nonetheless still likely an overestimate unless all HIV 
primary care clinics were evaluated. Second, lack of 
resources threatens the frequency and accuracy of the 
underlying census data that inform the incidence denomi-
nator. In Uganda, for example, the most recent census 
was postponed for two years [27]. In addition, with patients 
from rural areas coming to urban areas for health care 
when they are ill, it is unclear what the effective popula-
tion base for the urban- based registries is. Finally, in both 
resource- limited and resource- rich settings, the geographic- 
based approach of incidence estimation typically leaves 
us not knowing which KS cases are HIV infected, and 
the denominator of the at- risk HIV- infected persons is 
also not precisely known. Thus, we cannot directly learn 
the incidence of KS in the group that is most affected–
those with HIV infection.
Instead of targeting a geographic population, we used 
healthcare populations to estimate KS incidence in HIV- 
infected individuals, an approach that has been attempted 
by others in Africa (Table 4). Prior to the advent of potent 
ART in the country, Mbulaiteye et al. used a record link-
age algorithm to match data from an HIV primary care 
clinic in Kampala, Uganda, to the local cancer registry [8]. 
KS incidence among these untreated HIV- infected adults 
Figure 4. Incidence rate of Kaposi sarcoma (per 100,000 person- years) over time among HIV- infected patients at three healthcare systems in East 
Africa. Line represents locally weighted scatterplot smoothing (LOWESS). AMPATH denotes Academic Model Providing Access to Healthcare in 
western Kenya; ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; and IDI denotes Infectious Diseases Institute in Kampala, 
Uganda. Q represents quarter of the calendar year.
(A) (B)
(D)(C)
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was 240/100,000 person- years. Several reasons likely explain 
why their estimate is considerably lower than ours. First, 
they relied upon a pathology department- based cancer 
registry during an era when clinical diagnosis alone was 
quite common. Second, the person- time denominator was 
assembled by counting the time from each patient’s clinic 
enrollment to administrative database closure unless a death 
was definitively known; this likely overestimated the at- risk 
person- time and underestimated KS incidence. Finally, 
without the ability to match on unique ID number, the 
record linkage process was admittedly imperfect and may 
have resulted in failure of some KS diagnoses to be matched. 
From within the ART era, Asiimwe et al. [28] estimated 
KS incidence in the context of a home- based clinical trial 
of ART monitoring strategies in Uganda. Because of the 
trial setting, the patients were all presumably followed 
closely, and all KS diagnoses were biopsy confirmed, thus 
enhancing the sensitivity and specificity of KS ascertain-
ment. At- risk person- time was also carefully measured. 
Their “on- ART” KS incidence estimate (340/100,000 person- 
years) was higher than ours (286/100,000 person- years) but, 
with only 18 KS cases, considerably less precise (95% CI: 
201–537/100,000 person- years). In addition, having been 
conducted early in the ART rollout, the estimate from 
Asiimwe et al. may reflect an overall lower underlying CD4 
count structure than our present population. Most recently, 
Akarolo- Anthony et al. also used a record linkage algorithm 
to match HIV- infected patients (presumably a mix of both 
those on and off ART) registered at healthcare facilities 
to the cancer registry in Abuja, Nigeria [29]. Estimated 
KS incidence was substantially lower at 4.9/100,000 person- 
years, over 90% less than estimates in comparable African 
populations. Besides the imperfect record linkage process, 
the authors suggest that the low incidence was because of 
the failure of clinicians to diagnose KS when it was present. 
We additionally speculate that the cancer registry did not 
record an important fraction of KS diagnoses made on 
clinical grounds only in ambulatory settings.
An approach more similar to ours was used to estimate 
KS incidence among HIV- infected adults attending any one 
of six HIV clinics in Southern Africa IeDEA [13, 30] 
(Table 4). In this work, the incidence of KS off ART 
(1682/100,000 person- years in South Africa from Bohlius 
et al. [13]) was much higher than our estimate, but the 
two on- ART estimates were lower (138/100,000 person- years 
from South Africa [13] and 178/100,000 person- years from 
4 Southern African countries in Rohner et al. [30]). Regarding 
the difference in off- ART KS incidence, a difference in 
CD4+ T- cell distribution between the regions is a theoreti-
cal explanation, but this is difficult to examine because 
Bohlius et al. provide CD4 count stratum- specific KS inci-
dences only according to CD4 count at clinic enrollment. 
Given this limitation, only the <50 cells/mm3 stratum can 
be appropriately evaluated, and when doing so, KS incidence 
in Southern Africa was still considerably higher (3281/100,000 
person- years) than our estimate (1818/100,000 person- years). 
Another potential explanation is that although not described 
in the report, it is believed, on historical grounds, that a 
large fraction of the KS diagnoses in Southern Africa were 
clinical only, which are prone to false positivity [25]. 
Regarding the on- ART incidence estimate, examination of 
the CD4 count stratum- specific estimates reveals that the 
overall higher estimate in East Africa is largely explained 
by our higher estimate in the <50 cells/mm3 group 
(1357/100,000 person- years) compared to Bohlius et al. 
(188/100,000 person- years) or Rohner et al. (403/100,000 
person- years). We speculate–as do the original authors–that 
this may be because of underascertainment of KS during 
the 2004 to 2007 period in Southern Africa. In fact, in 
Rohner et al., when analysis is restricted to 2007 to 2010, 
overall KS incidence on ART (224/100,000 person- years) 
is much closer to our estimate, and, if children were excluded, 
it would even be closer. Finally, differences in underlying 
prevalence of KSHV may also contribute to the differences 
in KS incidence. Methodologic uncertainty in measuring 
KSHV infection status precludes clarity on this point, but 
we earlier found that, when using the same serologic assay 
in representative samples, KSHV prevalence was higher in 
Uganda than in Zimbabwe or South Africa [31].
As this study was conducted during the heart of the 
scale- up of ART in East Africa, it offers insights into the 
impact of ART on the development of KS. In what we 
believe is a unique analysis, we found that the prevalence 
of KS declined at the largest of our sites (AMPATH). 
Among several potential explanations for this, the most 
obvious is that more HIV- infected patients are achieving 
access to ART at earlier HIV disease stages and hence 
averting the development of KS while untreated in the 
community. KS incidence among those in care also declined, 
which is consistent with the growing proportion of patients 
on ART and achieving higher CD4 counts. Finally, the 
impact of ART is most clearly seen in the comparison of 
CD4 count stratum- specific KS incidences between ART 
users and non- ART users. Yet, none of these findings directly 
estimates what observers most commonly want to know: 
What is the reduction in KS incidence caused by ART if 
it could be tested in a randomized trial? As discussed in 
detail elsewhere [32], addressing this question is complex 
because of time- dependent confounding/mediation by CD4+ 
T- cell count in the available observational data. The solu-
tion to this analytical problem is more sophisticated than 
conventional regression allows and requires modeling tech-
niques beyond the scope of the current work.
While we believe this work is among the most com-
prehensive attempts of KS incidence estimation in Africa 
by virtue of the provision of training and biopsy capacity 
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to optimize the sensitivity and specificity of KS case ascer-
tainment and the large well- enumerated at- risk denominator, 
there are still limitations. The first is that biopsy confirma-
tion did not accompany all diagnoses, thus leaving open 
the possibility that some of the clinical- only KS diagnoses 
were incorrect. We know that during this time period, at 
these sites, an important fraction of clinically suspected 
cases of KS concurrently sent for pathologic interpretation 
did not get confirmed as KS [25]. Whether this fraction 
also holds true for clinical diagnoses not receiving patho-
logic interpretation is unknown. We speculate that the 
clinical training provided by IeDEA in KS differential diag-
nosis enhanced the positive predictive value of clinical- only 
diagnosis, but this cannot be proven without performing 
a biopsy on all such instances. A second limitation is unlike 
a true research- dedicated cohort, the patients in this study 
were not serially systematically evaluated for KS. Instead, 
KS ascertainment was made during the course of routine 
care by clinicians. We therefore may have missed cases 
and, more importantly, may have misclassified time of onset 
and hence grouping as prevalent versus incident KS or 
“off ART” versus “on ART.” Finally, some patients who 
developed KS while nominally on ART may have stopped 
using ART entirely and thus are misclassified in terms of 
ART exposure. While we do not believe that this is a 
sizeable fraction, it does require further investigation.
Our findings provide perspective about the impact of 
KS on the HIV healthcare system both now and into the 
future in East Africa. Our ASIR (334/100,000 person- years 
when limited to adults and 247/100,000 when extrapolated 
to include children) provides a good estimate of the overall 
burden that KS poses. To provide context, the most com-
mon cancer among women in the United States is breast 
(ASIR = 125/100,000 person- years) and among men is 
prostate (ASIR = 148/100,000 person- years); the ASIR for 
all cancers combined is 460/100,000/person- years [2]. 
Although KS incidence is not of the same magnitude as 
the “Big 3” in Africa (HIV, tuberculosis, and malaria), its 
relevance in the context of cancer is clear. Regarding the 
future, the UNAIDS’ 90- 90- 90 campaign [30] suggests that 
the ART- treated HIV- infected patient will become the rule 
rather than the exception in Africa. That said, our on- ART 
KS incidence estimate foreshadows the future, and several 
aspects of this determination merit mention. First, although 
KS incidence on ART is considerably lower than off ART, 
it remains at levels that exceed the aforementioned most 
common cancers in general populations. Thus, ART has 
not eliminated KS. Second, incidence is dependent upon 
ambient CD4 count, and all discussions about KS incidence 
on ART must be conditioned on this important determi-
nant. Among ART- treated patients who had “normalized” 
their CD4 count (>500 cells/mm3), KS incidence was con-
siderably lower (31/100,000 person- years) but, again, still 
comparable to other important cancers (e.g., pancreas, 
stomach, and colon) as measured in resource- rich regions 
[2]. Therefore, it is now a research imperative to establish 
why HIV- infected patients on ART still develop KS.
The same difficulties we described for the numerator 
and denominator in KS incidence estimation also apply 
to other cancers in the region, and hence, a healthcare 
system- based approach to incidence estimation should be 
considered for these as well. This is most relevant for 
HIV- infected populations for which the ART rollout has 
rapidly created a large well- enumerated primary care system 
but will likely apply to HIV- uninfected populations in 
the future as the lessons from the ART rollout get applied 
more generally. Again, the elegance of this approach rests 
primarily in the individual- level enumeration of a large 
at- risk population. If highly sensitive and specific diagnosis 
of a given cancer can be added to the population, accurate 
and precise cancer incidence estimation follows. We believe 
that this is most immediately plausible for cancers which 
feature feasible screening and case ascertainment, such as 
cervical, breast, and hepatocellular.
In summary, we have demonstrated how a strategic 
investment to improve diagnosis in combination with 
an already well- enumerated large denominator allowed 
us to use a healthcare system- based population to derive 
an improved estimate of the incidence of KS in East 
Africa. We found that, overall, KS incidence exceeds 
the most common cancers in resource- rich settings, but 
it is declining as the ART rollout extends. Yet, KS inci-
dence among patients on ART does not fall to zero, 
even among those with “normalized” CD4 counts. 
Attention now must turn to why HIV- infected patients 
on ART still develop KS.
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